The brain reward circuitry is thought to underlie the co-occurrence of attention-deficit/hyperactivity disorder (ADHD) and substance use disorder (SUD) and to possibly impact mood disorders. This study aimed to establish if any difference existed in the severity of depression symptomology between SUD comorbidity with and without ADHD. : A multi-centre, cross-sectional comparison study design drew study participants from substance use treatment facilities within South Africa.
View Article and Find Full Text PDFBackground: Attention-Deficit/Hyperactivity Disorder (ADHD) is commonly perceived as a cultural construct due to its disproportionate global representation, however limited data is available from Africa. Standardisation of screening tools in epidemiological studies is essential for global prevalence comparison, but tools such as the Adult ADHD Self-Report Scale (ASRS) have not been translated into African languages.
Objective: To assess the translation process followed in attempting to adapt the ASRS into an indigenous African language widely spoken within South Africa for cross-cultural research.
Background: Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder which typically presents in childhood. This diagnosis may often be overlooked in adulthood, particularly in psychiatric populations. The Adult ADHD Self-Report Scale (ASRS) is an internationally used and reliable screener; however, studies investigating its use in African populations are limited.
View Article and Find Full Text PDFExpert Rev Pharmacoecon Outcomes Res
June 2017
Co-occurring disorders (CODs) describe a Substance Use Disorder (SUD) accompanied by a comorbid psychiatric disorder. Attention-Deficit/Hyperactivity Disorder (ADHD) and mood disorders are common CODs with high prevalence rates in SUD populations. It is proposed that literature on a tri-condition presentation of ADHD, mood disorder and SUD is limited.
View Article and Find Full Text PDFJ Child Adolesc Ment Health
May 2015
Objective: Attention deficit hyperactivity disorder (ADHD) is a prevalent disorder affecting people in all age groups. Pharmacological treatment with psychostimulants, specifically methylphenidate, is first line management. The ideal dosing regimen of methylphenidate is debatable with daily use being considered harmful by many.
View Article and Find Full Text PDF